01 — Opening Hook
The Glucometer King With a CDMO Wildcard
Imagine a company that sells blood glucose strips to diabetics across India, suddenly announces a ₹825 crore (₹91 million USD) international contract manufacturing deal in February. Your first thought? Either they’re manufacturing pills for everyone’s secret stash, or this is genuine work from a global pharma customer who finally realized Indian CDMOs aren’t just cheap—they can actually execute. Morepen just proved it’s the latter. Q3 FY26 saw profit jump 77% YoY, revenue grow 13%, and the stock barely budged. Because the market still doesn’t trust a company that burned two years building reputation in glucometers but suddenly says, “Oh, by the way, we make active ingredients too.” Read on. This gets interesting.
What You’re About to Read: A company that’s either poised for exponential CDMO-led growth, or stuck in the middle of two businesses fighting for attention. The data will tell you which one.
02 — At a Glance
The Numbers Play: Q3 Profit Shock Edition
- Q3 Revenue₹462 Cr+13% YoY. 9-month growth at 4%. Quarterly beats 9M average—lumpiness or gunshot start?
- Q3 EBITDA₹46 Cr+41% YoY. Margin 10%. Finally, some backbone in profitability.
- Q3 PAT₹23 Cr+77% YoY. Exceptional income of ₹1.1 Cr helped. Strip that, still +73%. Real jump.
- EPS (Q3)₹0.50TTM ₹1.82. Stock at ₹37, P/E 26.5x. Pricey for 10.2% ROE.
- Medical Devices Revenue₹177 Cr (+44% YoY)Glucometers on fire. BP monitors steady. This is the cash cow.
- Pharma API Revenue₹249 Cr (+1% YoY)Flat growth. Legacy API prices collapsing. Chinese competitors playing ping-pong with margins.
The Brutal Truth: Medical devices roaring, pharma APIs suffocating on price wars, but CDMO deal promises salvation in 4–5 months. Timing? Convenient. Credibility? Watch execution.
03 — Management’s Key Commentary
What They Said (And What It Actually Means)
Management (Q3 Call): “We have secured a ₹825 crore multi-year CDMO mandate from an international customer. Supplies begin in 4–5 months. Execution spans 12–15 months.”
🎯 Translation: We just won a lottery ticket. It’s in our hand, but we haven’t cashed it yet. In 4–5 months we’ll know if we can actually deliver without blowing up our balance sheet.
Management: “Medical devices segment grew 44% YoY. Glucometers sold 2.33 billion test strips cumulatively; 16.85 million BP monitors in customer base. Dr. Morepen brand is now the market leader in point-of-care diagnostics.”
💪 Translation: This business actually works. Margins are real. Customers trust us. This is the only segment we know how to scale. And it’s still only 38% of Q3 revenue.
Management: “Pharma API business faces pricing pressure from Chinese competitors. However, we are expanding into higher-margin molecules like Dapagliflozin, Sitagliptin, and Linagliptin.”
😩 Translation: Our legacy bread-and-butter (Loratadine, Montelukast, Atorvastatin) is being commoditized. We’re praying new molecules save us. But they contribute <10% of API revenue today. Prayer is a strategy now, apparently.
Management: “We’ve approved ₹30 crore unsecured term loan from KEB Hana Bank and ₹50 crore from Woori Bank. Both 3-year tenure with promoter guarantee.”
💸 Translation: We’re borrowing aggressively to fund CDMO capex and capacity expansion. Debt climbing. If the CDMO deal doesn’t deliver, we’re over-leveraged on hope.
Management: “FY25 was the highest PAT in company history at ₹118 crore. We’re proposing a dividend after 23 years—₹0.20 per share.”
🎁 Translation: We finally made enough money to throw crumbs to shareholders. The dividend is 0.54% yield. Don’t expect more. We’re keeping cash for capex and CDMO execution bets.
Management: “HC granted stay on ₹117.94 crore GST SCN. We’ve already filed strong defense.”
⚖️ Translation: Shimla GST authorities think we over-claimed refunds. This is a sword hanging over our head. Stay is temporary. Real judgment could take 2–3 years. Worst case? We pay back with interest and penalties.
04 — Numbers Decoded
The Financial Scorecard
